Skip to main content

Table 3 Incidence rate per 100 patient-years and incidence rate ratio of hospitalized infection

From: Unincreased risk of hospitalized infection under targeted therapies versus methotrexate in elderly patients with rheumatoid arthritis: a retrospective cohort study

 

Young (14,668.59 PY)

Elderly (10,611.63 PY)

Older elderly (7,911.10 PY)

Number of HIs

473

534

804

Overall IR [95% CI]

3.20 [2.92–3.50]

4.99 [4.58–5.43]

10.14 [9.45–10.85]

IRR [95% CI] (vs. young)

Reference

1.56 [1.38–1.77]

3.17 [2.83–3.55]

IR [95% CI] during exposure to MTX

2.34 [2.03–2.69]

4.90 [4.39–5.46]

11.0 [10.1–12.0]

IR [95% CI] during exposure to bDMARDs/JAKIs

4.33 [3.84–4.87]

5.12 [4.47–5.86]

8.74 [7.75-–9.82]

IRR [95% CI] (bDMARDs/JAKIs vs. MTX)

1.85 [1.54–2.22]

1.05 [0.88–1.24]

0.79 [0.68–0.92]

  1. bDMARDs Biological disease-modifying antirheumatic drugs, CI Confidence interval, IR Incidence rate, IRR Incidence rate ratio, JAKIs Janus kinase inhibitors, MTX Methotrexate, PY Patient-year